Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer

BACKGROUND: Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce the risk of venous thromboembolism (VTE) compared with placebo for the primary thromboprophylaxis of ambulatory patients with cancer who are starting chemotherapy and are at intermediate-to-high risk of VTE. We ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimpton, Miriam, Kumar, Srishti, Wells, Philip S., Coyle, Doug, Carrier, Marc, Thavorn, Kednapa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Joule Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568073/
https://www.ncbi.nlm.nih.gov/pubmed/35040802
http://dx.doi.org/10.1503/cmaj.210523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568073/
https://www.ncbi.nlm.nih.gov/pubmed/35040802
http://dx.doi.org/10.1503/cmaj.210523

Ejemplares similares